 Home > Active Ingredient News > Antitumor Therapy > The first domestic "dual immunity" therapy was approved!

The first domestic "dual immunity" therapy was approved!

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

new bowling balls

process improvement project

xyzal 10 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

2021 Nian 10 Yue 12 days, Bristol-Myers Squibb today announced the world's first CTLA-4 inhibitors Yi Wo ^® (adalimumab Iraq horses injection) has been officially listed in China
.
As the first and the only country in the approved CTLA-4 inhibitors, Wo Yi and the PD-1 Ou Diwo inhibitors ^® (sodium Wu Li You monoclonal antibody injection) combined for unresectable, early Treated adult patients with non-epithelial malignant pleural mesothelioma

2021 Nian 10 Yue 12 days, Bristol-Myers Squibb today announced the world's first CTLA-4 inhibitors Yi Wo ^®^®(adalimumab Iraq horses injection) has been officially listed in China

Professor Lu Shun, Director of the Oncology Department of the Thoracic Hospital Affiliated to Shanghai Jiaotong University, said: “ Malignant pleural mesothelioma is a highly aggressive and rare cancer with limited treatment options and a 5- year survival rate of less than 10%
.

Breaking the 15 -year impasse new drugs, double immunotherapy bring lasting survival benefit for patients break 15 long-lasting drug-free survival benefit in deadlock, double immunotherapy for patients to bring

Malignant pleural mesothelioma is a rare, highly aggressive and fatal malignant tumor that originates from the pleural mesothelium

Due to the difficulty of diagnosis , most patients are already at an advanced stage at the time of diagnosis

The lack of effective treatment is the main reason for the low survival rate of patients with malignant pleural mesothelioma

As the only phase III clinical study that proves that first-line immunotherapy can improve the survival benefit of patients with unresectable malignant pleural mesothelioma , CheckMate-743 provides reliable evidence-based medical evidence for the approval of malignant pleural mesothelioma

CheckMate -743 is an open-label, multi-center, randomized phase III clinical study designed to evaluate the use of nivolumab combined with ipilimumab versus standard chemotherapy (pemetrexed combined with cisplatin or carboplatin) in the past The therapeutic effect of untreated patients with malignant pleural mesothelioma ( MPM ) ( n=605 )

" Compared with chemotherapy, dual immunotherapy further reduces the patient's risk of death by 27% .

Double immunotherapy era has come, ' to chemotherapy ' goal is expected to achieve double-immunotherapy era has come, ' to chemotherapy ' target is expected to achieve

Unlike chemotherapy, tumor immunotherapy fights tumors by activating the body's own immune system

Different from traditional treatment, immunotherapy may cause inflammatory symptoms in corresponding organs, called immune-related adverse reactions ( irAE ), with skin and gastrointestinal symptoms being the most common

Professor Wu Yilong , Life Director of Guangdong Provincial People’s Hospital and Honorary Director of Guangdong Lung Cancer Institute ( GLCI ) , said: Wu Yilong “ Through established adverse event management plans, Odivo and Yiwo first-line treatment of malignant pleural mesothelioma is safe and controllable.
The safety profile is consistent with the safety of the combination therapy in other tumor studies
.
Compared with chemotherapy, patients have the opportunity to achieve long-term survival
with a higher quality of life and fewer side effects .
With the advent of the era of dual immunotherapy we expected to eventually achieve ' to chemotherapy ' goals
.
"

In the latest "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Clinical Application of Immune Checkpoint Inhibitors (2021 Edition ) ", Odivo combined with Yiwo first-line treatment of non-epithelioid and epithelioid pleural mesothelioma became the only one to obtain Class I (Class 1 evidence) and Class II recommended (2 Class A evidence) therapeutic drugs
.

Up to now, in order to jointly Oudi Wo Wo Yi double immune-based combination therapy has five kinds of tumor 6 Xiang III showed a clinical study in overall survival ( OS benefit), including malignant pleural mesothelioma, non-small Cell lung cancer, metastatic melanoma, advanced renal cell carcinoma, and esophageal squamous cell carcinoma
.

It is reported that in order to help more patients achieve high-quality long-term survival and improve the accessibility of innovative drugs, Bristol-Myers Squibb teamed up with China Cancer Foundation on the basis of the original " Odivo Patient Assistance Project " when Yiwo was launched .
New indications for malignant pleural mesothelioma
.
Patients who meet the project criteria can voluntarily submit an application for assistance from Odiwo combined with Yiwo treatment
.
For details, please refer to the official website of the China Cancer Foundation
.

Ms.
Chen Siyuan, President of Bristol-Myers Squibb China and Hong Kong, said: “ As a pioneer in the field of immuno-oncology treatment, Bristol-Myers Squibb will separate the world’s first PD-1 inhibitor Odivo and the first CTLA-4 inhibitor
Yiwo into China to accelerate the global innovation drugs landing in China .
this double-approved immunotherapy for malignant pleural mesothelioma is the company launched ' China 2030 strategy ' first indication approved after a landmark
In the future, Bristol-Myers Squibb will continue to integrate into China’s booming innovation ecosystem, and is committed to becoming an innovation leader rooted in China and originating from China.
It will work with partners to continuously improve the availability of innovative drugs and change through scientific innovation.
The patient’s life
.
"

Reference

1.
https://gco.
iarc.
fr/today/data/factsheets/populations/160-china-fact-sheets.
pdf

2.
Daniel H Sterman, et al.
Epidemiology of malignant pleural mesothelioma .
UpToDate.

2.
Daniel H Sterman, et al.
Epidemiology of malignant pleural mesothelioma .
UpToDate.
Daniel H Sterman, et al.
Epidemiology of malignant pleural mesothelioma .
UpToDate.

3.
Tang Shanwei , et al .
Research progress in the treatment of malignant pleural mesothelioma .
Cancer progress .
2019,17(11): 1245-1250

3.
Tang Shanwei , et al .
Research progress in the treatment of malignant pleural mesothelioma .
Cancer progress .
2019,17(11): 1245-1250 3.
Tang Shanwei , et al .
Research progress in the treatment of malignant pleural mesothelioma .
Cancer progress .
2019, 17(11): 1245-1250

4.
Daniel H Sterman, et al.
Manifestations, initial evaluation and prognosis of malignant pleural mesothelioma UpToDate.

4.
Daniel H Sterman, et al.
Manifestations, initial evaluation and prognosis of malignant pleural mesothelioma UpToDate.
4.
Daniel H Sterman, et al.
Manifestations, initial evaluation and prognosis of malignant pleural mesothelioma UpToDate.

5.
American Cancer Society 2010-2016.

5.
American Cancer Society 2010-2016.
5.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.